TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07857837: A Phase 1, Multi-center, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Sulthiame (S-054502) in Participants With Varying Degrees of Renal Impairment and Matched Healthy Co

Sponsor: Shionogi · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$3,792,768

Rescue Site Savings

+$2,505,936

Unlock Full NCT07857837 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07857837 Rescue Dossier →